Athersys Stock News

Athersys (NASDAQ:ATHX) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued on Friday, Zacks.com reports. The firm presently has a $1.25 price objective on the biopharmaceutical companys stock. Zacks Investment Researchs price objective would suggest a potential upside of 21.36% from the companys current price. []

Wall Street brokerages expect Athersys, Inc. (NASDAQ:ATHX) to post ($0.07) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Athersys earnings, with estimates ranging from ($0.09) to ($0.05). Athersys reported earnings per share of ($0.11) in the same quarter last year, which suggests a positive []

Athersys Inc (NASDAQ: ATHX ) announced that a manuscript reporting data from its MUST-ARDS clinical trial have been published in the peer-reviewed medical journal , Intensive Care Medicine. MUST-ARDS Phase 1/2 trial evaluated the safety and efficacy of MultiStem (invimestrocel) cell therapy in patients with acute respiratory distress syndrome (ARDS). MultiStem treatment was well-tolerated, with no allergic or serious adverse Full story available on Benzinga.com

Athersys Inc (NASDAQ: ATHX) announced that a manuscript reporting data from its MUST-ARDS clinical trial have been published in the peer-reviewed medical journal, Intensive Care Medicine.  MUST-ARD

The stock price of Athersys Inc (NASDAQ: ATHX) increased by over 15% pre-market today. This is why it happened.

Livingston Group Asset Management CO operating as Southport Capital Management lowered its position in Athersys, Inc. (NASDAQ:ATHX) by 51.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 39,380 shares of the biopharmaceutical companys stock after selling 41,770 shares during the period. Livingston Group Asset Management []

During the last session, Athersys Inc. (NASDAQ:ATHX)s traded shares were 1.75 million, with the beta value of the company hitting -1.60. At the end of the trading day, the stocks price was $1.04, reflecting an intraday gain of 1.96% or $0.02. The 52-week high for the ATHX share is $3.03, that puts it down -191.35 Athersys Inc. (NASDAQ: ATHX) Is Down -11.86% In A Month. Could There Be Any Hope That It Will Rise Soon? Read More »

Amalgamated Bank raised its holdings in Athersys, Inc. (NASDAQ:ATHX) by 36.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 36,608 shares of the biopharmaceutical companys stock after purchasing an additional 9,689 shares during the quarter. Amalgamated Banks holdings in Athersys were worth $53,000 []

I covered Athersys' ischemic stroke trial earlier.

Athersys, Inc. (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Athersys, Inc. (NASDAQ:ATHX) was the recipient of a significant increase in short interest in the month of October. As of October 29th, there was short interest totalling 16,350,000 shares, an increase of 25.8% from the October 14th total of 13,000,000 shares. Based on an average daily volume of 1,240,000 shares, the days-to-cover ratio is presently […]

Athersys, Inc. (NASDAQ:ATHX) was the target of a large increase in short interest in October. As of October 29th, there was short interest totalling 16,350,000 shares, an increase of 25.8% from the October 14th total of 13,000,000 shares. Currently, 7.9% of the shares of the stock are short sold. Based on an average daily volume […]

Green Alpha Advisors LLC grew its position in Athersys, Inc. (NASDAQ:ATHX) by 7.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 191,242 shares of the biopharmaceutical companys stock after acquiring an additional 13,434 shares during the quarter. Green Alpha []

Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.